Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 9/20 | 0.44 |
| ▸ | METAP1 | P53582 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27561011 | 0.95 | SMN1; SMN2 (0.47) | SMN1; SMN2METAP2METAP1TSHRHTT | |
| SCHEMBL22751568 | 0.88 | METAP2 (0.46) | SMN1; SMN2METAP2METAP1HTTLMNA | |
| SCHEMBL11189746 | 0.88 | METAP2 (0.46) | SMN1; SMN2METAP2METAP1HTTLMNA | |
| SCHEMBL6899801 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRHTTLMNAALOX15 | |
| SCHEMBL13195821 | 0.81 | METAP2 (0.42) | SMN1; SMN2METAP2METAP1HTTLMNA | |
| SCHEMBL27749565 | 0.81 | METAP2 (0.43) | SMN1; SMN2METAP2METAP1TSHRLMNA | |
| SCHEMBL27749567 | 0.81 | METAP2 (0.43) | SMN1; SMN2METAP2METAP1TSHRLMNA | |
| SCHEMBL10087935 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRHTTLMNAALOX15 | |
| SCHEMBL18190838 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRHTTLMNAALOX15 | |
| SCHEMBL8079436 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRHTTLMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | ALKERMES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| CN-1173957-C | Substituted piperazones and their therapeutic use | L���������鹫˾ | 2004-11-03 | — | — | CN | disclosed |
| CN-1314895-A | Substituted piperazinones and therapeutic uses thereof | LAFON LABOR (FR) | 2001-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | SMN1; SMN2 649/4885METAP2 2271/4885METAP1 1478/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | SMN1; SMN2 1836/4885METAP2 3441/4885METAP1 3536/4885 |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | SMN1; SMN2 3792/4885METAP2 2205/4885METAP1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.